Open | - |
Close | - |
Volume / Avg. | 1.000 / 135.628K |
Day Range | - - - |
52 Wk Range | 0.901 - 8.170 |
Market Cap | $10.598M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 35 |
Short Interest | 0.57% |
Days to Cover | 1.26 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Mustang Bio (NASDAQ: MBIO) through any online brokerage.
Other companies in Mustang Bio’s space includes: Eterna Therapeutics (NASDAQ:ERNA), Imunon (NASDAQ:IMNN), Addex Therapeutics (NASDAQ:ADXN), Monopar Therapeutics (NASDAQ:MNPR) and Coeptis Therapeutics (NASDAQ:COEP).
The latest price target for Mustang Bio (NASDAQ: MBIO) was reported by Cantor Fitzgerald on Thursday, August 24, 2023. The analyst firm set a price target for 18.00 expecting MBIO to rise to within 12 months (a possible 1664.71% upside). 8 analyst firms have reported ratings in the last year.
The stock price for Mustang Bio (NASDAQ: MBIO) is $1.02 last updated March 18, 2024 at 5:16 PM EDT.
There are no upcoming dividends for Mustang Bio.
Mustang Bio’s Q1 earnings are confirmed for Friday, May 10, 2024.
There is no upcoming split for Mustang Bio.
Mustang Bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.